Both in R&D — Physical & Biological Sciences
MaxCyte vs IB Acquisition
Over the past year MXCT returned −21.3% and IBAC returned +5.7%; their daily moves had a correlation of 0.01.
MXCT −21.3% IBAC +5.7%Growth of $1, one year, split-adjusted
| Metric | MXCT | IBAC |
|---|---|---|
| Price | $1.18 | $11.10 |
| Market cap | $121.8M | $55.6M |
| Today | +1.72% | −1.77% |
| 1 month | −3.3% | +1.9% |
| 6 months | +74.5% | +3.6% |
| Year to date | −23.9% | +5.7% |
| 1 year | −22.9% | — |
| Revenue growth (YoY) | −14.5% | — |
| Gross margin | 77.0% | — |
| Net margin | −122.0% | — |
| P/E (TTM) | — | — |
| Price / sales | 3.9× | — |
| Net cash | $105.7M | — |
| Dividend yield | — | — |
| Volatility (60d) | 58.6% | 19.9% |
| Short % of float | 1.2% | 0.0% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).